Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity

BACKGROUND AND PURPOSE: Esophageal cancer incidence is increasing and is rarely curable. Hypoxic tumor areas cause resistance to conventional therapies, making them susceptible for treatment with hypoxia-activated prodrugs (HAPs). We investigated in vivo whether the HAP evofosfamide (TH-302) could i...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiegelberg, Linda, van Hoof, Stefan J., Biemans, Rianne, Lieuwes, Natasja G., Marcus, Damiënne, Niemans, Raymon, Theys, Jan, Yaromina, Ala, Lambin, Philippe, Verhaegen, Frank, Dubois, Ludwig J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Scientific Publishers 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913516/
https://www.ncbi.nlm.nih.gov/pubmed/31431383
http://dx.doi.org/10.1016/j.radonc.2019.06.034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913516/
https://www.ncbi.nlm.nih.gov/pubmed/31431383
http://dx.doi.org/10.1016/j.radonc.2019.06.034

Ejemplares similares